Manzano Stephen 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 3, 2021
Insider Transaction Report
Form 4
Manzano Stephen
SVP, General Counsel
Transactions
- Award
Restricted Stock Units
2021-03-01+67,568→ 67,568 total→ Class A Common Stock (67,568 underlying) - Award
Performance-Based Restricted Stock Units
2021-03-01+135,136→ 135,136 total→ Class A Common Stock (135,136 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]The restricted stock units vest in four equal annual installments beginning on March 1, 2022.
- [F3]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F4]Represents the maximum number of shares issuable under the performance-based restricted stock units.
- [F5]50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period.